[Primary aldosteronism: The Mayo Clinic approach]

Primary aldosteronism remains underdiagnosed despite being a major cause of secondary hypertension. While antihypertensive therapy controls blood pressure, it does not address the underlying aldosterone overproduction. This condition can lead to specific cardiovascular and renal damage if left untreated. Prior research has shown that delayed diagnosis often results in irreversible complications. No prior work had resolved how best to integrate PA screening into routine hypertension care. Existing guidelines suggest screening in selected high-risk groups, but broader implementation is limited. The Mayo Clinic approach aims to simplify case detection by removing barriers to testing. This paper addresses the diagnostic workflow and treatment decisions in PA patients.

The study aims to present a streamlined approach for diagnosing and managing primary aldosteronism. It focuses on eliminating unnecessary diagnostic steps and integrating testing into ongoing antihypertensive therapy. The goal is to improve detection rates without requiring medication adjustments. The authors propose a diagnostic pathway that reduces patient burden and healthcare costs. They emphasize the importance of timely intervention to prevent organ damage. The approach also considers the role of imaging and venous sampling in determining treatment options. The study highlights the need for patient-centered decision-making in treatment selection. It provides a framework for clinicians to follow in PA evaluation and treatment.

The Mayo Clinic approach uses a simplified diagnostic algorithm for PA detection. It does not require measuring plasma aldosterone concentration or plasma renin activity ratio. Testing can proceed while patients continue their antihypertensive medications. Confirmatory testing follows initial screening results. Computed tomography scans are used to identify adrenal pathology. Adrenal venous sampling is reserved for cases where imaging is inconclusive. Patient discussions guide the choice between pharmacological and surgical options. Laparoscopic adrenalectomy is recommended for unilateral disease.

The approach allows PA screening without altering antihypertensive therapy. Confirmatory testing is guided by imaging and venous sampling results. Patients with unilateral disease undergo laparoscopic adrenalectomy. Those with bilateral disease receive mineralocorticoid receptor antagonists. Treatment aims to normalize serum potassium levels. The method reduces diagnostic delays and improves patient compliance. It emphasizes the importance of patient education in treatment decisions. The protocol is designed for broad application in hypertension clinics.

The Mayo Clinic approach streamlines PA detection and treatment. It eliminates the need for specific medication adjustments before testing. The method supports diagnosis while patients remain on their current therapies. Imaging and venous sampling guide treatment decisions. Surgical options are reserved for unilateral cases. Medical therapy is preferred for bilateral disease. Patient involvement in decision-making is a key component. The approach aims to increase PA detection rates and reduce complications.